XAGEW
Longevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.75 | $391,764 | -$485,290 |
| 2025 Q4 | -1.21 | $472,982 | -$306,368 |
| 2025 Q3 | -0.83 | $425,864 | -$1M |
| 2025 Q2 | -0.09 | $503,612 | -$836,190 |
| 2025 Q1 | -0.07 | $510,353 | -$752,953 |
| 2024 Q4 | -0.04 | $17,479 | -$772,063 |
| 2024 Q3 | -0.14 | $20,519 | -$1M |
| 2024 Q2 | -0.16 | $12,320 | -$1M |